PREVENTION OF EVENTS WITH ANGIOTENSIN (PEACE)
Principal Investigator: Madeline Rice, Ph.D.
Co-Investigator: Sarah E. Fowler, Ph.D.
The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) trial is a randomized placebo controlled, multi-center multi-national trial initiated in November 1995 by the National Heart, Lung, and Blood Institute (NHLBI). The primary objective of the trial is to test whether the addition of the angiotensin converting enzyme (ACE) inhibitor, trandolapril, to standard therapy will reduce the incidence of cardiovascular mortality, non-fatal myocardial infarction, or the occurrence of a coronary artery bypass graft surgery (CABG) or percutaneous transluminal coronary angiography (PTCA) in patients with documented coronary artery disease and preserved left ventricular function. Over one hundred and eighty-five clinical centers in the United States, Puerto Rico, Canada, and Italy completed recruiting 8,290 patients for the study in June 2000. Follow-up ended on December 31, 2003 with an average follow-up of over 4 years. The George Washington University Biostatistics Center serves as the Clinical and Statistical Coordinating Center for this trial.)